Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Delcath Systems Q3 2026 Results: Net Income $6.95M, Up 737.6% YoY

Delcath Systems reported a significant increase in product revenue to $89.2 million for the first nine months of 2026, resulting in a net income of $8.6 million compared to $4.6 million in the prior year. The company maintained a strong liquidity position with $104.3 million in cash and short-term investments as of September 30, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue35.120.6
Gross profit31.217.9
Profit before tax8.00.4
Net income7.00.8
EPS (diluted, $ a share)$0.17$0.02

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+737.6%
Revenue, year on year+70.7%
Gross margin88.8%
Operating margin20.3%
Source

10-Q filed with the SEC, NASDAQ: DCTH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Delcath Systems, Inc.: key numbers

Share price
$19.87Close, Nov 16
Market cap
$691M
Shares outstanding
34.79MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Delcath Systems, Inc.

All →
4:11 PM ET Form 4
Insider Selling

Delcath Systems Director Bridget A. Martell Sells $489K of Stock

Bridget A. Martell, Director, sold 22,500 shares of Delcath Systems, Inc. at $21.66 to $22.26 a share (average $21.71) in 2 transactions, worth $489K in total on Nov 12, 2026. Shares held after the trade: 0 (-100.0%).

Value
$489K
Shares
22,500
Average price
$21.71
Role
Director
Holding change
-100.0%
Trade date
Nov 12, 2026
8:04 AM ET 8-K
Financial Results

Delcath Systems Financial Results

Delcath Systems reported Q3 2026 total revenue of $35.1 million, a 70% increase year-over-year, driven by strong HEPZATO KIT sales in the U.S. The company achieved net income of $7.0 million and increased its full-year 2026 revenue guidance to a range of $115 million to $117 million.

Term
Q3 2026

“We are pleased with the continued momentum in our business, with meaningful progress across both commercial operations and clinical development. Growing physician experience with HEPZATO, strong engagement across our treatment center network, and increasing interest in its use alongside systemic therapies reinforce our confidence in the long-term opportunity.”

Gerard Michel, Chief Executive Officer of Delcath Systems

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.